![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities
|
|
|
EASL 2022 June 22-26 London
Michael Shen, Zhixin Zong, Naqvi Mohammed, Katie Zomorodi, Luisa M Stamm, William Delaney, Nicole White
Assembly Biosciences, Inc., South San Francisco, CA, USA
![0625221](../images/062622/062622-6/0625221.gif)
![0625222](../images/062622/062622-6/0625222.gif)
![0625223](../images/062622/062622-6/0625223.gif)
![0625224](../images/062622/062622-6/0625224.gif)
![0625225](../images/062622/062622-6/0625225.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|